News - Janssen


Current filters:


Popular Filters

73 to 97 of 110 results

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA


There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries…

BiotechnologyJanssenJohnson & JohnsonNeurologicalNorth AmericaNucyntaOncologyPharmaceuticalRegulationZytiga

Janssen initiates Ph III study of sirukumab, being developed with GSK


Janssen Biologics (Ireland), part of US health care giant Johnson & Johnson (NYSE: JNJ), has initiated…

Anti-Arthritics/RheumaticsGlaxoSmithKlineJanssenJohnson & JohnsonPharmaceuticalResearchsirukumab

Pharmacyclics gets second $50 million milestone from Janssen


California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

J&J and Pfizer drop bapineuzumab development for Alzheimer's


There was disappointing - though not really unexpected - news yesterday for US health care giant Johnson…

bapineuzumabElanJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Pharmacyclics gets $50 milestone from J&J on ibrutinib progress


California, USA-based Pharmacyclics (Nasdaq: PCYC) says it that enrolment of the fifth patient in the…

FinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's


US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Janssen in-licenses insulin-producing beta cells from Evotec


German biotech firm Evotec AG (EVT: TecDAX) has licensed to Janssen Pharmaceuticals, a unit of US health…

BiotechnologyDiabetesEvotecJanssenJohnson & JohnsonLicensing

US priority review for two Xarelto sNDAs; one dropped


The US Food and Drug Administration has assigned a priority review designation to the supplemental New…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Janssen buys Germany's CorImmun


US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag GmbH yesterday…

Cardio-vascularCorImmun GmbHJanssenJohnson & JohnsonMergers & AcquisitionsPharmaceutical

US physicians to increase use of Zytiga in chemo-naive prostate cancer patients


Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson…

DendreonJanssenJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeResearchZytiga

Johnson & Johnson units file for new Zytiga use in USA and EU


Janssen Research & Development, a subsidiary of US drugs giant Johnson & Johnson (NYSE: JNJ), has submitted…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationZytiga

Janssen files NDA with FDA for canagliflozin in type 2 diabetes


Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy


Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

UK's NICE does U-turn, recommending Zytiga as Janssen cuts price


UK drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has reversed an earlier…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

73 to 97 of 110 results

Back to top